Suppr超能文献

3D打印微混合器与喷雾干燥相结合用于抗菌微粒的肺部给药。

Integration of 3D-printed micromixers and spray drying for pulmonary delivery of antimicrobial microparticles.

作者信息

Anaya Brayan J, Kara Aytug, Raposo Rafaela, Tirado Diego F, Lalatsa Aikaterini, González-Burgos Elena, Serrano Dolores R

机构信息

Pharmaceutics and Food Technology Department, Faculty of Pharmacy, Universidad Complutense de Madrid, Plaza RamónSpain y Cajal s/n, 28040 Madrid, Spain.

Sección Departamental de Fisiología, Faculty of Pharmacy, Universidad Complutense de Madrid (UCM), 28040 Madrid, Spain.

出版信息

Int J Pharm. 2025 Apr 15;674:125493. doi: 10.1016/j.ijpharm.2025.125493. Epub 2025 Mar 17.

Abstract

Pulmonary drug delivery is crucial for treating respiratory diseases, requiring precise particle engineering for optimal therapeutic efficacy. This study demonstrates a novel integration of 3D-printed microfluidic micromixers with spray drying technology to produce inhalable azithromycin (AZM) microparticles targeting lung delivery. The formulation demonstrated effective deep lung deposition at both 30 L/min and 60 L/min flow rates. At 30 L/min, AZM-loaded microparticles achieved enhanced performance with 1.2-fold higher Fine Particle Fraction (FPF) < 5 µm and 1.4-fold higher FPF < 3 µm compared to 60 L/min. Microparticles (25 mg) can deliver an efficacious dose of AZM to the lung, exceeding the reported epidemiological cut-off for Haemophilus influenzae (4 mg/L) by approximately five-fold while maintaining high human bronchial epithelial cell viability (> 94 %). The antibacterial efficacy against H. influenzae was confirmed, demonstrating the therapeutic potential against lung pathogens. The successful deep lung deposition at both air flow rates reflects the robustness of the formulation design, making it suitable for diverse patient populations with varying inspiratory capabilities, including children and elderly patients.

摘要

肺部给药对于治疗呼吸道疾病至关重要,需要精确的颗粒工程以实现最佳治疗效果。本研究展示了一种将3D打印微流控微混合器与喷雾干燥技术新颖结合的方法,用于制备靶向肺部递送的可吸入阿奇霉素(AZM)微粒。该制剂在30 L/min和60 L/min的流速下均显示出有效的肺部深部沉积。在30 L/min时,与60 L/min相比,载有AZM的微粒表现出增强的性能,细颗粒分数(FPF)<5 µm提高了1.2倍,FPF <3 µm提高了1.4倍。微粒(25 mg)可将有效剂量的AZM递送至肺部,超过报告的流感嗜血杆菌流行病学临界值(4 mg/L)约五倍,同时保持较高的人支气管上皮细胞活力(> 94%)。证实了对流感嗜血杆菌的抗菌效果,证明了其对肺部病原体的治疗潜力。在两种气流速度下均成功实现肺部深部沉积,反映了制剂设计的稳健性,使其适用于包括儿童和老年患者在内的具有不同吸气能力的各种患者群体。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验